Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
AMD Market Disrupto | Clearside Biomedical's CLS-AX aims to revolutionize wet AMD treatment with flexible dosing, potentially addressing a significant unmet need in ophthalmology |
Financial Crossroads | With $20M in cash, Clearside faces funding challenges for pivotal trials. Analyst price targets range from $4 to $8, suggesting significant upside potential |
Innovative Pipeline | Explore CLS-AX's unique product profile, which could allow for personalized treatment regimens and extended dosing intervals beyond the current six-month standard |
Competitive Landscape | Delve into Clearside's position in the lucrative AMD market, where its 91.05% gross profit margin and differentiated approach could provide a competitive edge |
Metrics to compare | CLSD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLSDPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −1.5x | −0.5x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | −0.8x | 0.3x | 2.6x | |
Price / LTM Sales | 10.3x | 1.7x | 3.2x | |
Upside (Analyst Target) | - | 81.8% | 41.7% | |
Fair Value Upside | Unlock | 22.1% | 6.1% | Unlock |